Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Inventory (2020 - 2025)

GeneDx Holdings has reported Inventory over the past 6 years, most recently at $14.0 million for Q4 2025.

  • Quarterly results put Inventory at $14.0 million for Q4 2025, up 31.0% from a year ago — trailing twelve months through Dec 2025 was $14.0 million (up 31.0% YoY), and the annual figure for FY2025 was $14.0 million, up 31.0%.
  • Inventory for Q4 2025 was $14.0 million at GeneDx Holdings, up from $10.6 million in the prior quarter.
  • Over the last five years, Inventory for WGSWW hit a ceiling of $44.2 million in Q3 2022 and a floor of $8.8 million in Q4 2023.
  • Median Inventory over the past 5 years was $12.5 million (2023), compared with a mean of $19.8 million.
  • Biggest five-year swings in Inventory: surged 42.82% in 2022 and later tumbled 78.84% in 2023.
  • GeneDx Holdings' Inventory stood at $33.5 million in 2021, then crashed by 59.16% to $13.7 million in 2022, then crashed by 35.77% to $8.8 million in 2023, then grew by 21.34% to $10.6 million in 2024, then skyrocketed by 31.0% to $14.0 million in 2025.
  • The last three reported values for Inventory were $14.0 million (Q4 2025), $10.6 million (Q3 2025), and $11.9 million (Q2 2025) per Business Quant data.